Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249044 | 1.00 | SLC5A1 (0.32) | SLC5A1SLC5A2P2RY2TSHRHTT | |
| SCHEMBL14928761 | 1.00 | SLC5A1 (0.32) | SLC5A1SLC5A2P2RY2TSHRHTT | |
| SCHEMBL17463503 | 1.00 | SLC5A1 (0.32) | SLC5A1SLC5A2P2RY2TSHRHTT | |
| SCHEMBL18118104 | 1.00 | SLC5A1 (0.32) | SLC5A1SLC5A2P2RY2TSHRHTT | |
| SCHEMBL17424240 | 0.90 | — | — | |
| SCHEMBL21082362 | 0.84 | SLC5A2 (0.36) | SLC5A1SLC5A2TSHRHTTSMN1; SMN2 | |
| SCHEMBL16477816 | 0.81 | P2RY2 (0.39) | P2RY2 | |
| SCHEMBL17463480 | 0.81 | P2RY2 (0.35) | P2RY2 | |
| SCHEMBL14928488 | 0.81 | P2RY2 (0.35) | P2RY2 | |
| SCHEMBL18118506 | 0.81 | P2RY2 (0.35) | P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9587003-B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | MODERNATX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9504734-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNATX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160152678-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-02 | — | — | US | disclosed |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-04-28 | — | — | US | disclosed |
| US-9301993-B2 | Modified polynucleotides encoding apoptosis inducing factor 1 | MODERNA THERAPEUTICS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9283287-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9220792-B2 | Modified polynucleotides encoding aquaporin-5 | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9216205-B2 | Modified polynucleotides encoding granulysin | MODERNA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9149506-B2 | Modified polynucleotides encoding septin-4 | MODERNA THERAPEUTICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-09-03 | — | — | US | disclosed |
| US-20140255468-A1 | MODIFIED POLYNUCLEOTIDES ENCODING PROGRAMMED CELL DEATH 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | SLC5A1 4290/4885SLC5A2 4610/4885P2RY2 4062/4885 |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | SLC5A1 4726/4885SLC5A2 4790/4885P2RY2 3286/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | SLC5A1 1056/4885SLC5A2 1138/4885P2RY2 558/4885 |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | AQP1, AQP3, AQP4 | SLC5A1 1121/4885SLC5A2 1512/4885P2RY2 999/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | SLC5A1 4597/4885SLC5A2 4610/4885P2RY2 3344/4885 |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | SLC5A1 4726/4885SLC5A2 4790/4885P2RY2 3286/4885 |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | SLC5A1 2789/4885SLC5A2 3290/4885P2RY2 1526/4885 |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | POLRMT, POLN, GALNT1 | SLC5A1 1021/4885SLC5A2 2298/4885P2RY2 2757/4885 |
| US-20140255468-A1 | MODIFIED POLYNUCLEOTIDES ENCODING PROGRAMMED CELL DEATH 1 | MSH2, POLRMT, PDCD1 | SLC5A1 3959/4885SLC5A2 4723/4885P2RY2 3134/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | SLC5A1 4226/4885SLC5A2 4515/4885P2RY2 3235/4885 |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MSH2, APAF1, MCL1 | SLC5A1 4515/4885SLC5A2 4845/4885P2RY2 4131/4885 |
| US-20160152678-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | SLC5A1 4677/4885SLC5A2 4759/4885P2RY2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.